{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T21:11:41Z","timestamp":1785532301531,"version":"3.56.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Rein Therapeutics, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease with limited treatment options. LTI-03 promotes alveolar epithelial cell survival and reduces profibrotic protein expression in experimental models of IPF. In this Phase 1b, randomized, double-blind, placebo-controlled dose-escalation study, 24 participants with IPF were randomized 3:1 to inhaled LTI-03 5\u2009mg\/day (N\u2009=\u20099), LTI-03 10\u2009mg\/day (N\u2009=\u20099) or placebo (N\u2009=\u20096) for 14 days and included in all analyses (ClinicalTrials.gov: NCT05954988). The primary endpoint was the incidence of treatment-emergent adverse events (TEAEs). Exploratory analyses included pharmacokinetics and disease-related biomarkers. LTI-03 was well-tolerated, with no treatment-related discontinuations, no severe TEAEs, and no evidence of airway obstruction by spirometry and associated symptoms. In deep bronchial brushings, both LTI-03 doses significantly reduced interleukin-11 (p\u2009=\u20090.0406 at 5\u2009mg\/day; p\u2009=\u20090.044 at 10\u2009mg\/day) and thymic stromal lymphopoietin (p\u2009=\u20090.0256 at 5\u2009mg\/day; p\u2009=\u20090.0128 at 10\u2009mg\/day) versus placebo. The 10\u2009mg\/day dose suppressed collagen type 1 alpha chain 1 (p\u2009=\u20090.0248), CXC chemokine ligand 7 (p\u2009=\u20090.0248) and galectin-7 (p\u2009=\u20090.0332). Other measured biomarkers were not significantly changed. The favorable safety profile and reductions in disease-related biomarkers support further evaluation of inhaled LTI-03 for IPF. This study was fully funded by Rein Therapeutics, Inc.<\/jats:p>","DOI":"10.1038\/s41467-026-75291-3","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:54:47Z","timestamp":1785524087000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1301-8800","authenticated-orcid":false,"given":"Philip L.","family":"Molyneaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8854-3605","authenticated-orcid":false,"given":"Nikhil A.","family":"Hirani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collin C. K.","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4251-4988","authenticated-orcid":false,"given":"Tejaswini","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanzira","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Kaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Lucia","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yago Amigo Pinho","family":"Jannini-Sa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Windsor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale J.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Shoemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory M.","family":"Hogaboam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BreAnne","family":"MacKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2187-0975","authenticated-orcid":false,"given":"Andreas","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"75291_CR1","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra1705751","volume":"378","author":"DJ Lederer","year":"2018","unstructured":"Lederer, D. J. & Martinez, F. J. Idiopathic Pulmonary Fibrosis. N. Engl. J. Med. 378, 1811\u20131823 (2018).","journal-title":"N. Engl. J. Med."},{"key":"75291_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.74","volume":"3","author":"FJ Martinez","year":"2017","unstructured":"Martinez, F. J. et al. Idiopathic Pulmonary Fibrosis. Nat. Rev. Dis. Prim. 3, 17074 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"75291_CR3","doi-asserted-by":"publisher","first-page":"797292","DOI":"10.3389\/fphar.2021.797292","volume":"12","author":"Q Mei","year":"2022","unstructured":"Mei, Q., Liu, Z., Zuo, H., Yang, Z. & Qu, J. Idiopathic Pulmonary Fibrosis: An update on pathogenesis. Front Pharm. 12, 797292 (2022).","journal-title":"Front Pharm."},{"key":"75291_CR4","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1056\/NEJMoa2414108","volume":"392","author":"L Richeldi","year":"2025","unstructured":"Richeldi, L. et al. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N. Engl. J. Med. 392, 2193\u20132202 (2025).","journal-title":"N. Engl. J. Med."},{"key":"75291_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12931-021-01714-y","volume":"22","author":"M Belhassen","year":"2021","unstructured":"Belhassen, M., Dalon, F., Nolin, M. & Van Ganse, E. Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis. Respir. Res 22, 135 (2021).","journal-title":"Respir. Res"},{"key":"75291_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/cells11010143","volume":"11","author":"K Takehara","year":"2022","unstructured":"Takehara, K. et al. Differential discontinuation profiles between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis. Cells 11, 143 (2022).","journal-title":"Cells"},{"key":"75291_CR7","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1084\/jem.20061536","volume":"203","author":"XM Wang","year":"2006","unstructured":"Wang, X. M. et al. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J. Exp. Med. 203, 2895\u20132906 (2006).","journal-title":"J. Exp. Med."},{"key":"75291_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2019.104315","volume":"111","author":"R Kulshrestha","year":"2019","unstructured":"Kulshrestha, R. et al. Caveolin-1 as a critical component in the pathogenesis of lung fibrosis of different etiology: Evidences and mechanisms. Exp. Mol. Pathol. 111, 104315 (2019).","journal-title":"Exp. Mol. Pathol."},{"key":"75291_CR9","doi-asserted-by":"publisher","first-page":"1417834","DOI":"10.3389\/fphar.2024.1417834","volume":"15","author":"J Fan","year":"2024","unstructured":"Fan, J., Zheng, S., Wang, M. & Yuan, X. The critical roles of caveolin-1 in lung diseases. Front Pharm. 15, 1417834 (2024).","journal-title":"Front Pharm."},{"key":"75291_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1165\/rcmb.2016-0034OC","volume":"56","author":"YY Sanders","year":"2017","unstructured":"Sanders, Y. Y. et al. Epigenetic regulation of caveolin-1 gene expression in lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 56, 50\u201361 (2017).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"75291_CR11","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1016\/j.ajpath.2018.07.005","volume":"188","author":"MR Nagaraja","year":"2018","unstructured":"Nagaraja, M. R. et al. p53 Expression in lung fibroblasts is linked to mitigation of fibrotic lung remodeling. Am. J. Pathol. 188, 2207\u20132222 (2018).","journal-title":"Am. J. Pathol."},{"key":"75291_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12014-019-9226-4","volume":"16","author":"Y Tian","year":"2019","unstructured":"Tian, Y. et al. Quantitative proteomic characterization of lung tissue in idiopathic pulmonary fibrosis. Clin. Proteom. 16, 6 (2019).","journal-title":"Clin. Proteom."},{"key":"75291_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1165\/rcmb.2017-0289OC","volume":"60","author":"MS Hohmann","year":"2019","unstructured":"Hohmann, M. S., Habiel, D. M., Coelho, A. L., Verri, W. A. & Hogaboam, C. M. Quercetin enhances ligand-induced apoptosis in senescent idiopathic pulmonary fibrosis fibroblasts and reduces lung fibrosis in vivo. Am. J. Respir. Cell Mol. Biol. 60, 28\u201340 (2019).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"75291_CR14","doi-asserted-by":"publisher","first-page":"L480","DOI":"10.1152\/ajplung.00295.2024","volume":"329","author":"L Fan","year":"2025","unstructured":"Fan, L. et al. p53-miR-34a Feedback in lung fibroblasts regulates antifibrotic effects of CSP7, nintedanib and pirfenidone. Am. J. Physiol. Lung Cell Mol. Physiol. 329, L480\u2013L498 (2025).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"75291_CR15","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.3390\/ijms23063316","volume":"23","author":"S Komatsu","year":"2022","unstructured":"Komatsu, S., Fan, L., Idell, S., Shetty, S. & Ikebe, M. Caveolin-1-derived peptide reduces ER stress and enhances gelatinolytic activity in IPF fibroblasts. Int J. Mol. Sci. 23, 3316 (2022).","journal-title":"Int J. Mol. Sci."},{"key":"75291_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-14832-4","volume":"12","author":"S Venkatesan","year":"2022","unstructured":"Venkatesan, S., Fan, L., Tang, H., Konduru, N. V. & Shetty, S. Caveolin-1 scaffolding domain peptide abrogates autophagy dysregulation in pulmonary fibrosis. Sci. Rep. 12, 11086 (2022).","journal-title":"Sci. Rep."},{"key":"75291_CR17","first-page":"A2307","volume":"205","author":"B MacKenzie","year":"2022","unstructured":"MacKenzie, B. et al. Caveolin scaffolding domain LTI-03 modulates both inflammatory and fibrotic responses in aged mice after bleomycin challenge. Am. J. Respir. Crit. Care Med. 205, A2307 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"75291_CR18","doi-asserted-by":"publisher","first-page":"113437","DOI":"10.1016\/j.isci.2025.113437","volume":"28","author":"B MacKenzie","year":"2025","unstructured":"MacKenzie, B. et al. LTI-03 peptide demonstrates anti-fibrotic activity in ex vivo lung slices from patients with IPF. iScience 28, 113437 (2025).","journal-title":"iScience"},{"key":"75291_CR19","doi-asserted-by":"publisher","first-page":"A4691","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A4691","volume":"211","author":"YAP Jannini-Sa","year":"2025","unstructured":"Jannini-Sa, Y. A. P., Coelho, A. L., Mackenzie, B. & Hogaboam, C. M. Evaluating alveolar regenerative properties of caveolin scaffolding peptides (CSD) in three dimensional (3D) alveolospheres from IPF and normal donor lung samples. Am. J. Respir. Crit. Care Med. 211, A4691 (2025).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"75291_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat2848","volume":"11","author":"AS Marudamuthu","year":"2019","unstructured":"Marudamuthu, A. S. et al. Caveolin-1-derived peptide limits development of pulmonary fibrosis. Sci. Transl. Med. 11, eaat2848 (2019).","journal-title":"Sci. Transl. Med."},{"key":"75291_CR21","first-page":"632","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Development of an excipient-free peptide dry powder inhalation for the treatment of pulmonary fibrosis. Mol. Pharm. 17, 632\u2013644 (2020).","journal-title":"Mol. Pharm."},{"key":"75291_CR22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/thorax.58.4.339","volume":"58","author":"SS Birring","year":"2003","unstructured":"Birring, S. S. et al. Development of a symptom-specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 58, 339\u2013343 (2003).","journal-title":"Thorax"},{"key":"75291_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2174\/1874312901206010116","volume":"6","author":"E Tourkina","year":"2012","unstructured":"Tourkina, E. & Hoffman, S. Caveolin-1 signaling in lung fibrosis. Open Rheumatol. J. 6, 116\u2013122 (2012).","journal-title":"Open Rheumatol. J."},{"key":"75291_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.matbio.2013.03.005","volume":"32","author":"D Gvaramia","year":"2013","unstructured":"Gvaramia, D., Blaauboer, M. E., Hanemaaijer, R. & Everts, V. Role of caveolin-1 in fibrotic diseases. Matrix Biol. 32, 307\u2013315 (2013).","journal-title":"Matrix Biol."},{"key":"75291_CR25","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2174\/1874467214666211130155902","volume":"15","author":"G Shivani","year":"2022","unstructured":"Shivani, G. & Lokesh Kumar, B. Caveolin-1: A promising therapeutic target for diverse diseases. Curr. Mol. Pharm. 15, 701\u2013715 (2022).","journal-title":"Curr. Mol. Pharm."},{"key":"75291_CR26","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3390\/cells12040554","volume":"12","author":"S Shetty","year":"2023","unstructured":"Shetty, S. & Idell, S. Caveolin-1-Related intervention for fibrotic lung diseases. Cells 12, 554 (2023).","journal-title":"Cells"},{"key":"75291_CR27","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.chest.2018.08.1083","volume":"154","author":"G Raghu","year":"2018","unstructured":"Raghu, G. et al. Idiopathic Pulmonary Fibrosis: Prospective, case-controlled study of natural history and circulating biomarkers. Chest 154, 1359\u20131370 (2018).","journal-title":"Chest"},{"key":"75291_CR28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12931-018-0730-2","volume":"19","author":"G Sgalla","year":"2018","unstructured":"Sgalla, G. et al. Idiopathic pulmonary fibrosis: pathogenesis and management. Respir. Res. 19, 32 (2018).","journal-title":"Respir. Res."},{"key":"75291_CR29","first-page":"41","volume":"4","author":"TW Permatasari","year":"2024","unstructured":"Permatasari, T. W. & Karuniawati, A. Post-Bronchoscopy infections: A literature review. J. Clin. Microbiol. Infect. Dis. 4, 41\u201349 (2024).","journal-title":"J. Clin. Microbiol. Infect. Dis."},{"key":"75291_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12931-018-0845-5","volume":"19","author":"A Guenther","year":"2018","unstructured":"Guenther, A. et al. The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respir. Res 19, 141 (2018).","journal-title":"Respir. Res"},{"key":"75291_CR31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1056\/NEJMoa2008470","volume":"384","author":"A Waxman","year":"2021","unstructured":"Waxman, A. et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N. Engl. J. Med. 384, 325\u2013334 (2021).","journal-title":"N. Engl. J. Med."},{"key":"75291_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1089\/jamp.2013.1042","volume":"27","author":"TE Corcoran","year":"2014","unstructured":"Corcoran, T. E., Niven, R., Verret, W., Dilly, S. & Johnson, B. A. Lung deposition and pharmacokinetics of nebulized cyclosporine in lung transplant patients. J. Aerosol Med Pulm. Drug Deliv. 27, 178\u2013184 (2014).","journal-title":"J. Aerosol Med Pulm. Drug Deliv."},{"key":"75291_CR33","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.chest.2020.04.066","volume":"158","author":"A Adegunsoye","year":"2020","unstructured":"Adegunsoye, A. et al. Circulating plasma biomarkers of survival in antifibrotic-treated patients With idiopathic pulmonary fibrosis. Chest 158, 1526\u20131534 (2020).","journal-title":"Chest"},{"key":"75291_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1450798","volume":"16","author":"X He","year":"2025","unstructured":"He, X. et al. Serum surfactant protein D as a significant biomarker for predicting occurrence, progression, acute exacerbation, and mortality in interstitial lung disease: a systematic review and meta-analysis. Front Immunol. 16, 1450798 (2025).","journal-title":"Front Immunol."},{"key":"75291_CR35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12931-020-01582-y","volume":"21","author":"K Ikeda","year":"2020","unstructured":"Ikeda, K. et al. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan. Respir. Res. 21, 316 (2020).","journal-title":"Respir. Res."},{"key":"75291_CR36","doi-asserted-by":"crossref","unstructured":"Jenkins, R. G. et al. Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis. ERJ Open Research, 00558-2023 (2024).","DOI":"10.1183\/23120541.00558-2023"},{"key":"75291_CR37","doi-asserted-by":"publisher","first-page":"00335-2023","DOI":"10.1183\/23120541.00335-2023","volume":"10","author":"TM Maher","year":"2024","unstructured":"Maher, T. M. et al. Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trial. ERJ Open Res. 10, 00335-2023 (2024).","journal-title":"ERJ Open Res."},{"key":"75291_CR38","first-page":"PA4257","volume":"64","author":"P Schafer","year":"2024","unstructured":"Schafer, P. et al. Development of a multi-biomarker risk score based on serum proteins by the Prognostic Lung Fibrosis Consortium (PROLIFIC). Eur. Respir. J. 64, PA4257 (2024).","journal-title":"Eur. Respir. J."},{"key":"75291_CR39","doi-asserted-by":"publisher","first-page":"e0194803","DOI":"10.1371\/journal.pone.0194803","volume":"13","author":"J Lee","year":"2018","unstructured":"Lee, J. et al. Bronchoalveolar lavage (BAL) cells in idiopathic pulmonary fibrosis express a complex pro-inflammatory, pro-repair, angiogenic activation pattern, likely associated with macrophage iron accumulation. PLoS One 13, e0194803 (2018).","journal-title":"PLoS One"},{"key":"75291_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1159856","volume":"14","author":"T Zhao","year":"2023","unstructured":"Zhao, T. et al. Identification and validation of chemokine system-related genes in idiopathic pulmonary fibrosis. Front Immunol. 14, 1159856 (2023).","journal-title":"Front Immunol."},{"key":"75291_CR41","doi-asserted-by":"publisher","first-page":"eaaw1237","DOI":"10.1126\/scitranslmed.aaw1237","volume":"11","author":"B Ng","year":"2019","unstructured":"Ng, B. et al. Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis. Sci. Transl. Med. 11, eaaw1237 (2019).","journal-title":"Sci. Transl. Med."},{"key":"75291_CR42","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41577-022-00735-y","volume":"23","author":"R Ebina-Shibuya","year":"2023","unstructured":"Ebina-Shibuya, R. & Leonard, W. J. Role of thymic stromal lymphopoietin in allergy and beyond. Nat. Rev. Immunol. 23, 24\u201337 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"75291_CR43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12890-017-0380-z","volume":"17","author":"JU Lee","year":"2017","unstructured":"Lee, J. U. et al. Upregulation of interleukin-33 and thymic stromal lymphopoietin levels in the lungs of idiopathic pulmonary fibrosis. BMC Pulm. Med. 17, 39 (2017).","journal-title":"BMC Pulm. Med."},{"key":"75291_CR44","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.4049\/jimmunol.1300588","volume":"191","author":"A Datta","year":"2013","unstructured":"Datta, A. et al. Evidence for a functional thymic stromal lymphopoietin signaling axis in fibrotic lung disease. J. Immunol. 191, 4867\u20134879 (2013).","journal-title":"J. Immunol."},{"key":"75291_CR45","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu, G. et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 198, e44\u2013e68 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"75291_CR46","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1183\/09031936.05.00034805","volume":"26","author":"MR Miller","year":"2005","unstructured":"Miller, M. R. et al. Standardisation of spirometry. Eur. Respir. J. 26, 319\u2013338 (2005).","journal-title":"Eur. Respir. J."},{"key":"75291_CR47","first-page":"10007","volume":"1","author":"MS Espindola","year":"2023","unstructured":"Espindola, M. S. et al. Translational studies reveal the divergent effects of simtuzumab targeting LOXL2 in Idiopathic Pulmonary Fibrosis. Fibros. (Hong. Kong) 1, 10007 (2023).","journal-title":"Fibros. (Hong. Kong)"},{"key":"75291_CR48","unstructured":"Romano, J., Kromrey, J. D., Coraggio, J. & Skowronek, J. Appropriate statistics for ordinal level data: should we really be using t-test and Cohen\u2019s d for evaluating group differences on the NSSE and other surveys? In Proceedings of the Annual meeting of the Florida Association of Institutional Research, Cocoa Beach, FL, 1-3 February (2006)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75291-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75291-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75291-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:07:52Z","timestamp":1785524872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75291-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75291"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75291-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.L.C., Y.A.P.J.S. and S.K. declare no competing interests. All other authors declare the following financial and non-financial competing interests: P.M. reports institutional grants from AstraZeneca, GSK, Asthma & Lung UK and Action for Pulmonary Fibrosis; consulting fees from Hoffman\u2013La Roche, Boehringer Ingelheim, AstraZeneca, Trevi, Qureight, Endevour, and Redx; speaker fees from Boehringer Ingelheim and Hoffman\u2013La Roche; Data Safety Monitoring Board fees from United Therapeutics; and stock options in Qureight. N.H. reports institutional grants\/contracts from Nerre Therapeutics and Redx Pharma; consulting fees from Arrowhead, Boehringer Ingelheim, Tribune and Trevi; and unpaid advisory board participation for TIPAL IPF UK and CHORUS fibrosing HP UK. C.C., C.M.H. and A.G. report institutional support, grants, and\/or consulting fees from Rein Therapeutics. T.K. reports consulting fees for Rein Therapeutics, Boehringer Ingelheim, United Therapeutics, Puretech Health, Vicore Pharma, Bristol Myers Squibb, and Mediar; advisory board participation for Boehringer Ingelheim, United Therapeutics, Puretech Health, and Bristol Myers Squibb. T.Z. reports institutional clinical trial support from Rein Therapeutics; institutional grants\/contracts from Genentech, Boehringer Ingelheim, Avalyn, and Pliant Therapeutics; advisory board fees from Avalyn, Trevi, and Boehringer Ingelheim; speaker fees from Boehringer Ingelheim; and travel reimbursement from Avalyn. R.J.K. reports support related to the present work from Nicosof, LLC; institutional grants\/contracts from NIH and multiple industry sponsors; royalties from UpToDate; consulting and honoraria from Amgen, Boehringer Ingelheim and others; advisory board participation for multiple pharmaceutical companies; stock ownership in Doximity and Air Cycle Systems; and receipt of medical writing support from industry. B.M. and J.B.W. are employees of Rein Therapeutics and hold stock or stock options; J.B.W. serves as Chief Executive Officer and board member and is an inventor on company patents. D.J.C. is a shareholder in Rein Therapeutics, receives consulting fees and has patents licensed to the company. S.A.S. reports consulting fees from Rein Therapeutics, service on the Data Safety Monitoring Board for the present study and a related Phase 1a study, and stock ownership in Rein Therapeutics. A.L.C., Y.A.P.J.S. and S.K. declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7620"}}